10-Q: China Pharma Holdings Faces Going Concern Doubts Amid Losses

China Pharma Holdings, Inc. reported a reduced net loss for the first half of 2025, but continues to face substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the six months ended June 30, 2025, significantly improved to $1.31 million, compared to $2.39 million for the same period in 2024.
• Revenue for the six months ended June 30, 2025, decreased by 5.8% to $2.16 million from $2.29 million in the prior year period.
• Gross loss for the six months ended June 30, 2025, improved to $0.22 million, down from $1.31 million in the prior year, with gross loss margin improving from 56.9% to 10.3%.
• Operating loss for the six months ended June 30, 2025, decreased to $1.41 million from $2.31 million in the prior year.
• Cash and cash equivalents remained stable at $0.63 million as of June 30, 2025, compared to $0.63 million as of December 31, 2024.
• Current liabilities exceeded current assets by $2.5 million as of June 30, 2025.
• The company had an accumulated deficit of $45.3 million as of June 30, 2025.
• Net cash provided by operating activities was $0.23 million for the six months ended June 30, 2025, a significant improvement from $0.66 million used in the prior year period.
• A 1-for-10 reverse stock split was implemented effective April 15, 2025, and all share and per share amounts have been retroactively restated.
• The company's Chairperson, Chief Executive Officer, and Interim Chief Financial Officer, Ms. Li, advanced an additional $0.24 million during Q2 2025, bringing the total owed to her to $1,407,607 as of June 30, 2025.

Sentiment

Score: 3

Explanation: While there were improvements in net loss and operating cash flow compared to the prior year, the company explicitly states 'substantial doubt about its ability to continue as a going concern.' The accumulated deficit is high, current liabilities exceed current assets, and there's a heavy reliance on related-party funding. The overall financial position remains highly precarious, warranting a low sentiment score despite some positive trends in loss reduction.

Positives

• Net loss for the six months ended June 30, 2025, decreased by 45.2% to $1.31 million from $2.39 million in the prior year.
• Gross loss significantly improved, decreasing from $1.31 million to $0.22 million, with gross loss margin improving from 56.9% to 10.3% for the six months ended June 30, 2025.
• Operating loss decreased by 38.9% to $1.41 million from $2.31 million for the six months ended June 30, 2025.
• Net cash provided by operating activities was $0.23 million for the six months ended June 30, 2025, a positive shift from $0.66 million used in the prior year period.
• Research and development expenses decreased to $0.05 million for the six months ended June 30, 2025, from $0.20 million in the prior year.
• A research and development subsidy of $0.15 million was received for the six months ended June 30, 2025, due to a refund from a defaulted outsourced project partner.
• The CNS Cerebral & Cardio Vascular product category saw a 7% revenue increase to $0.75 million for the six months ended June 30, 2025.
• The Digestive Diseases product category saw a 38% revenue increase to $0.11 million for the six months ended June 30, 2025.

Negatives

• The company's current liabilities exceeded current assets by $2.5 million as of June 30, 2025.
• An accumulated deficit of $45.3 million as of June 30, 2025, indicates significant historical losses.
• Revenue for the six months ended June 30, 2025, decreased by 5.8% to $2.16 million compared to the prior year.
• General and administrative expenses increased significantly to $0.95 million for the six months ended June 30, 2025, from $0.58 million in the prior year.
• The Anti-Viral/ Infection & Respiratory product category experienced an 11% revenue decrease to $1.25 million for the six months ended June 30, 2025.
• The 'Other' product category experienced a 64% revenue decrease to $0.04 million for the six months ended June 30, 2025.
• The allowance for inventory obsolescence increased to $1,000,888 as of June 30, 2025, from $574,071 as of December 31, 2024.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to current liabilities exceeding current assets by $2.5 million, an accumulated deficit of $45.3 million, and anticipated continued operating losses.
• There is no assurance that management's plans to alleviate going concern issues (enhancing advance payment sales, strengthening receivables collection, exploring nutrition products, securing additional bank loans, and reducing costs) will be fully executed or successful.
• Strategic alternatives being pursued are not considered probable of effective implementation as they are not finalized and not entirely within the company's control.
• Operations are substantially conducted in the PRC, exposing the company to political, economic, and legal risks, including fluctuations in foreign currency exchange rates and changes in governmental policies.
• The company faces concentration risk with one customer accounting for 11.5% of sales and two customers accounting for 63.5% and 13.7% of accounts receivable for the six months ended June 30, 2025.
• Concentration risk also exists with three suppliers accounting for 24.9%, 19.4%, and 16.4% of raw material purchases, and three products accounting for 32.8%, 22.8%, and 13.5% of revenue for the six months ended June 30, 2025.
• The company's PRC subsidiary, Helpson, is subject to PRC laws requiring allocation of 10% of after-tax income to statutory surplus reserve accounts until balances reach 50% of registered capital, restricting dividend distribution to the parent company.
• Chinese government controls on RMB conversion and remittance of foreign currencies out of China may restrict Helpson from transferring net assets to the parent company.
• A material weakness in internal control over financial reporting exists due to a lack of accounting financial reporting personnel knowledgeable in U.S. GAAP.

Future Outlook

Management anticipates operating losses to continue for the foreseeable future due to production costs, debt service, and selling/administrative costs. To address going concern issues, the company plans to enhance its advance payment sales model, strengthen accounts receivable collection, explore strategic alternatives for launching nutrition products, and seek additional bank loans collateralized by existing property, plant, and equipment. Cost reduction measures across procurement, production, human resources, and marketing are also planned, including consolidating purchasing, optimizing production cycles, efficient personnel deployment, and data-driven marketing. However, there is no assurance these initiatives will be fully executed or resolve the going concern conditions.

Management Comments

• "The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and selling and administrative costs."
• "To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable."
• "Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products."
• "In addition, management believes that the Company’s existing property, plant and equipment can serve as collateral to support additional bank loans."
• "The Company will implement multiple measures simultaneously across procurement, production, human resources, and marketing to reduce operating costs."
• "Management believes that, if successfully implemented, these measures may improve the Company’s cash position and allow the Company to fund its operations in the next twelve months, however, there can be no assurance that the Company will be able to fully execute the planned initiatives, achieve its strategic alternatives, and resolve the conditions raising substantial doubt about its ability to continue as a going concern."
• "We may seek additional debt or equity financing as necessary when we believe the market conditions are the most advantageous to us and/or require us to reduce certain discretionary spending, which could have a material adverse effect on our ability to achieve our business objectives."

Industry Context

The company operates in the Chinese pharmaceutical market, which is heavily influenced by government policies such as Centralized Procurement (CP) activities. CP has significantly reduced drug prices and requires consistency evaluation for generic drugs, leading to slow progress across the industry due to dynamic policy changes and ROI considerations. The company is also exploring the comprehensive healthcare field, aligning with the Chinese government's 'Healthy China 2030' initiative, and has launched products like Noni enzyme, sanitizers, and masks in response to market needs and health trends.

Corporate Governance

Related Party Transactions

• The Chairperson, Chief Executive Officer, and Interim Chief Financial Officer, Ms. Li, advanced an additional $0.24 million during the second quarter of 2025, bringing the total owed to her (recorded as Borrowings from related parties) to $1,407,607 as of June 30, 2025.
• A loan agreement with Chairperson Li for RMB 4,770,000 ($738,379) at 4.35% interest, originally due within one year, has been extended annually and is currently due July 9, 2026.
• Compensation payable to Chairperson Li is included in Other payables, totaling $1,603,506 as of June 30, 2025.
• The company's Chief Executive Officer and Chair of the Board (Zhilin Li) personally guaranteed a new line of credit for RMB 5,000,000 and pledged personal assets as collateral.
• The company's Chief Executive Officer and Chair of the Board (Zhilin Li) personally guaranteed a three-year revolving loan for RMB 10,000,000.

Stakeholder Impact

• **Shareholders:** Face significant risk due to the 'going concern' warning, accumulated deficit, and potential for future dilution from capital raises. Reverse stock splits have adjusted share counts and per-share metrics.
• **Employees:** The company plans to optimize staffing levels and implement targeted incentives to improve work efficiency, which could imply workforce adjustments.
• **Customers:** May experience changes in product availability or pricing due to the company's strategic adjustments in response to Centralized Procurement policies and exploration of new nutrition products.
• **Suppliers:** The company plans to consolidate purchasing activities to enhance bargaining power, potentially impacting supplier relationships and terms.
• **Creditors:** The company's reliance on lines of credit and related-party borrowings, along with the 'going concern' warning, indicates elevated credit risk. Personal guarantees from the CEO/Chair provide some additional security for certain loans.

Next Steps

• Enhance the sales model of advance payment.
• Further strengthen the collection of accounts receivable.
• Explore strategic alternatives to accelerate the launch of nutrition products.
• Utilize existing property, plant, and equipment as collateral to support additional bank loans.
• Implement multiple measures simultaneously across procurement, production, human resources, and marketing to reduce operating costs.
• Evaluate the impact of the recently issued accounting standards ASU 2024-03 and ASU 2025-01 on consolidated financial statements and disclosures.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on the condensed consolidated financial statements.

Key Dates

Recommendation

The company explicitly states 'substantial doubt about its ability to continue as a going concern,' which is a critical red flag for investors. Despite some improvements in net loss and operating cash flow, the underlying financial structure remains weak with a significant accumulated deficit and current liabilities exceeding current assets. The heavy reliance on related-party funding and personal guarantees from the CEO for bank loans highlights the company's inability to secure financing on its own merits. While management has plans to address these issues, their success is not assured and not entirely within the company's control. The material weakness in internal controls further adds to the risk profile. For a seasoned investor, these factors collectively point to a highly speculative and risky investment, making a 'strong sell' recommendation appropriate.

Keywords

Pharmaceuticals, China, SEC Filing, 10-Q, Financial Results, Going Concern, Drug Manufacturing, Healthcare, Reverse Stock Split, Corporate Governance, Risk Management, Zhilin Li